|
HU215581B
(hu)
|
1989-07-06 |
1999-01-28 |
Regents Of The University Of California |
Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
|
|
WO1994000599A2
(en)
|
1992-06-18 |
1994-01-06 |
Whittier Institute For Diabetes And Endocrinology |
Process for detection of neoplastic disease
|
|
AU6446194A
(en)
|
1993-03-17 |
1994-10-11 |
Whittier Institute For Diabetes And Endocrinology, The |
Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
|
|
US6517872B1
(en)
|
1995-06-12 |
2003-02-11 |
Yeda Research And Development Co., Ltd. |
FGFR3 as a marker for mesenchymal skeletal progenitor cells
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
US20030143676A1
(en)
|
1999-03-25 |
2003-07-31 |
Genesis Research And Development Corporation Limited |
Fibroblast growth factor receptors and methods for their use
|
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
|
AU5214500A
(en)
|
1999-05-05 |
2000-11-21 |
Centre National De La Recherche Scientifique (C.N.R.S.) |
Means for detecting and treating pathologies linked to fgfr3
|
|
DE20023659U1
(de)
|
1999-10-06 |
2005-07-07 |
Tigenix N.V. |
Molekulare Marker zum Testen der phänotypischen Stabilität von Zellpopulationen und Zellpopulationen für die autologe Transplantation
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
EP1469878B1
(en)
|
2002-01-31 |
2011-03-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Fgfr agonists
|
|
WO2004003179A1
(en)
|
2002-06-27 |
2004-01-08 |
The University Of Queensland |
Differentiation modulating agents and uses therefor
|
|
WO2004022095A1
(en)
|
2002-09-04 |
2004-03-18 |
Abtech |
Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
|
|
JP2007524566A
(ja)
|
2002-12-20 |
2007-08-30 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
レセプターとリガンドの間の相互作用の調節の方法
|
|
WO2004074506A2
(en)
|
2003-02-13 |
2004-09-02 |
Mergen Ltd |
Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
|
|
EP1611252B1
(en)
|
2003-03-26 |
2009-07-29 |
Progenika Biopharma, S.A. |
In vitro method to detect bladder transitional cell carcinoma
|
|
IL156495A0
(en)
|
2003-06-17 |
2004-01-04 |
Prochon Biotech Ltd |
Use of fgfr3 antagonists for treating t cell mediated diseases
|
|
EP1544213B1
(en)
|
2003-12-19 |
2008-02-20 |
Charité - Universitätsmedizin Berlin |
Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
|
|
EP1697420A2
(en)
|
2003-12-19 |
2006-09-06 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
ES2374822T3
(es)
|
2004-02-24 |
2012-02-22 |
Allergan, Inc. |
Ensayo de selección de toxinas botul�?nicas.
|
|
WO2005115363A2
(en)
|
2004-05-25 |
2005-12-08 |
Yale University |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
AU2005302083A1
(en)
|
2004-11-04 |
2006-05-11 |
Fibron Limited |
Treatment of B-cell malignancies
|
|
EP1659175A1
(en)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Alterations in seborrheic keratoses and their applications
|
|
EP1699826B1
(en)
|
2005-01-05 |
2009-03-11 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
AU2006227816B2
(en)
|
2005-03-15 |
2012-04-05 |
Allergan, Inc. |
Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
|
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
JP2009511613A
(ja)
|
2005-10-17 |
2009-03-19 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
神経細胞接着分子ｌ１のペプチド断片を含む新規ｆｇｆ受容体結合化合物
|
|
KR20080080525A
(ko)
|
2005-12-08 |
2008-09-04 |
노파르티스 아게 |
유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
|
|
US8101721B2
(en)
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
WO2008127707A1
(en)
|
2007-04-13 |
2008-10-23 |
Dana Farber Cancer Institute, Inc. |
Receptor tyrosine kinase profiling
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
AU2009219437B2
(en)
|
2008-02-25 |
2014-10-16 |
Nestec S.A. |
Drug selection for breast cancer therapy using antibody-based arrays
|
|
WO2009146033A2
(en)
|
2008-03-31 |
2009-12-03 |
Sma Foundation |
Compositions and methods for modulating smn activity
|
|
KR101590495B1
(ko)
|
2008-05-29 |
2016-02-01 |
갤럭시 바이오테크, 엘엘씨 |
염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
|
|
EP2313435A4
(en)
*
|
2008-07-01 |
2012-08-08 |
Aveo Pharmaceuticals Inc |
FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
|
|
AR073770A1
(es)
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
MA33208B1
(fr)
|
2009-03-25 |
2012-04-02 |
Genentech Inc |
Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
|
|
RU2012134637A
(ru)
|
2010-01-14 |
2014-02-20 |
Йейл Юниверсити |
Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
|
|
TWI452136B
(zh)
*
|
2010-11-17 |
2014-09-11 |
中外製藥股份有限公司 |
A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
|
|
US8790651B2
(en)
*
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
WO2013088191A1
(en)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
|
|
PL2824181T3
(pl)
|
2012-03-08 |
2019-02-28 |
Astellas Pharma Inc. |
Nowa fuzja fgfr3
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US20150292030A1
(en)
|
2012-11-27 |
2015-10-15 |
Board Of Regents, The University Of Texas System |
Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
|
|
WO2014161075A1
(en)
|
2013-04-05 |
2014-10-09 |
University Health Network |
Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
|
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
|
|
BR112017017700A2
(pt)
|
2015-02-19 |
2018-07-31 |
Bioclin Therapeutics Inc |
métodos, composições e kits para tratamento do câncer
|
|
SG11201906249PA
(en)
|
2017-02-06 |
2019-08-27 |
Rainier Therapeutics Inc |
Methods, compositions, and kits for treatment of cancer
|